

Botensilimab Biosimilar - Research Grade

Product Code: ICH5412

More Information

Species Reactivity: Human

Target: CTLA4 α 1/2

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Botensilimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P09793;P16410

Shipping Conditions: Blue ice

background: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory checkpoint that restrains early T-cell activation and is among the most studied targets in cancer immunotherapy research. As an unconjugated, non-therapeutic analog of botensilimab, this human IgG1-kappa recombinant antibody is supplied for research use only (RUO). It is an ultra-pure, low-endotoxin preparation built to in vivo standards and manufactured in scalable milligram-to-gram quantities for high-throughput laboratories. Researchers use it in checkpoint functional assays, T-cell activation and Treg studies, ADCC analysis, in vitro screening and in vivo syngeneic models exploring CTLA-4 biology.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks